What is Lifesci Capital’s Estimate for Immunome Q1 Earnings?

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at Lifesci Capital issued their Q1 2025 earnings per share estimates for shares of Immunome in a research note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will post earnings per share of ($0.61) for the quarter. Lifesci Capital currently has a “Outperform” rating and a $20.00 price objective on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

Separately, Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Monday, March 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $27.17.

Immunome Stock Down 1.8 %

NASDAQ:IMNM opened at $8.77 on Thursday. The firm has a market capitalization of $699.64 million, a PE ratio of -1.08 and a beta of 1.93. Immunome has a twelve month low of $8.39 and a twelve month high of $26.70. The stock’s 50-day simple moving average is $9.98 and its 200 day simple moving average is $11.80.

Insider Buying and Selling

In related news, CEO Clay B. Siegall bought 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 8.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently modified their holdings of IMNM. FMR LLC boosted its position in Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after acquiring an additional 13,757 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Enavate Sciences GP LLC acquired a new position in Immunome in the fourth quarter valued at approximately $36,939,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Immunome by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock worth $24,243,000 after buying an additional 246,447 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Immunome by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock worth $13,054,000 after buying an additional 21,396 shares during the period. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.